Oncology Market In China Outpaces Pharma Industry; Targeted Therapies Enjoy Fastest Growth - Citi Research
This article was originally published in PharmAsia News
SHANGHAI - Although anti-infective drugs still dominate China's pharma market with roughly one-fourth of the total drug sales in hospitals, China's oncology market is outpacing the larger global market
You may also be interested in...
Wearing two hats as a hematologist and China’s health minister, Zhu Chen says basic research and policymaking are interrelated and mutually beneficial.
The government will boost insurance premiums and maximum reimbursement for rural populations, and it sets its eyes on reforming hospital compensation.
In a recent report, Kantar Health takes a deep dive into China’s breast cancer market, where cost considerations play a larger role than in the West.